Vanda Pharmaceuticals Inc. Common Stock (VNDA)

FairStock Score: 38/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Vanda as a Graham-style asset buyer, and the numbers give me little to underwrite. Vanda sells medicines such as Fanapt, HETLIOZ, PONVORY, and NEREUSTM, so there is real commercial activity. But in fiscal Q2 2026, the quarter ended 2026-06-30, it reported revenue of $50.5 million and a net loss of $62.5 million, or diluted EPS of -$1.04. That is a -123.72% net margin: it spent far more than it brought in. The deterioration is not one quarter: fiscal 2023, the year ended 2023-12-31, had net income of $2.5 million; fiscal 2024, the year ended 2024-12-31, had a net loss of $18.9 million; and fiscal 2025, the year ended 2025-12-31, had a net loss of $220.5 million on revenue of $216.1 million. Sales grew from $192.6 million in fiscal 2023 to $216.1 million in fiscal 2025, but profitability collapsed.

In plain English: Vanda Pharmaceuticals sells prescription medicines for conditions such as schizophrenia, bipolar disorder, sleep problems, and multiple sclerosis. The business looks weak right now: it brings in about $50 million a quarter but is losing even more, and it is using up cash. The share price is low compared with the value of its net assets, but the deep losses make it hard to call the stock a clear bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer